Pharmaron Beijing Co., Ltd. provided earnings guidance for the six months ended June 30, 2025. For the period, the company estimated revenue to be: RMB 6,333.0436 million to RMB 6,501.1775 million, growth compared with the same period of last year: 13% to 16%. Same period last year revenue was RMB 5,604.4634 million.
Net profit attributable to owners of the parent estimated to be: RMB 679.1758 million to RMB 712.5779 million, decrease compared with the same period of last year: 36% to 39%. Same period last year Profit was RMB 1,113.4030 million. Basic earnings per share estimated to be: RMB 0.3858 to RMB 0.4048.
Same period last year Basic earnings per share was RMB 0.6282. Reasons for changes in results: Impact of principal business - The Company remained steadfast in implementing its core strategy of developing an end-to-end, fully integrated and multiple modalities-capable services platform with global footprints. Guided by customer demand, the Company further deepened its global footprint while strengthening its technological capabilities.
In the first half of 2025, the Company's revenue is estimated to increase by 13% to 16% year-on-year; the net profit attributable to owners of the parent excluding non-recurring gains or losses increased by 34% to 39% year-on-year. At the midpoint of the estimated results, in the second quarter of 2025, the Company's revenue increased by 13.11% year-on-year; the net profit attributable to owners of the parent excluding non-recurring gains or losses increased by 23.33% year-on-year. Impact of non-recurring gains or losses - As mentioned above, the non-recurring gains or losses attributable to owners of the parent during the reporting period amounted to approximately RMB 60 million to RMB 70 million.
The non-recurring gains or losses attributable to owners of the parent in the same period of last year were RMB 647.5201 million mainly due to the disposal of equity in PROTEOLOGIX, INC. The non-recurring gains or losses decreased by approximately RMB 577.5201 million to RMB 587.5201 million. Under the circumstances where the main business continues to improve, mainly due to the decrease in non-recurring gains and losses, the net profit attributable to owners of the parent decreased by 36% to 39% as compared with the same period of the last year.
